Stereodefined Polycyclic Steroids via Intramolecular Friedel-Crafts Alkylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current synthetic and semisynthetic routes for producing steroid and tetracyclic terpenoid compounds are inefficient and limited, making it difficult to access diverse, stereodefined molecules with unnatural stereochemistry, which are needed for advanced drug development and research, particularly for targeting estrogen receptors in cancers like gliomas.
Innovation Solution
Development of concise and stereoselective synthetic methods, including intramolecular Friedel-Crafts alkylation, Heck reactions, and oxidative dearomatization, to produce stereodefined polycyclic compounds with quaternary centers, enabling the creation of potent and selective ERβ agonists like Compounds 100 and 101, which can target glioma cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If semisynthetic routes starting from naturally occurring steroids are used, then readily available starting materials can be utilized, but synthesis of unnatural ent-steroids is impossible due to the mirror image backbone of natural molecules
Solution Approach 1:
The patent applies inversion by developing de novo synthesis routes that construct the steroid backbone from scratch rather than starting with natural steroids. This allows access to both natural and unnatural (ent-) enantiomers by controlling the stereochemistry during synthesis, specifically through asymmetric catalysis and chiral pool approaches that can produce either enantiomer selectively.
Solution Approach 2:
The synthesis is divided into modular segments including formation of the hydrindane core, construction of the tetracyclic steroid backbone, and sequential functionalization steps. This segmentation allows independent optimization of each stage and enables access to diverse stereoisomers by varying conditions at different synthetic stages.
2Adaptability or versatility
If complex synthetic routes are used to access diverse stereodefined molecules, then unnatural enantiomers can be produced, but synthesis efficiency and productivity decrease
Solution Approach 1:
The patent employs preliminary asymmetric induction early in the synthesis sequence to establish the correct stereochemistry at key quaternary centers before subsequent transformations. This preliminary action with chiral catalysts or chiral auxiliaries prevents the need for later stereochemical corrections and streamlines the overall synthesis of diverse stereodefined molecules.
Solution Approach 2:
The synthesis utilizes parameter changes including variation of catalysts, solvents, temperatures, and reaction conditions to control stereochemistry and optimize yields at different stages. By systematically adjusting these parameters, the method achieves high efficiency in producing diverse stereodefined steroid and terpenoid analogs.
3Ease of manufacture
If existing chemical synthesis pathways are used, then some steroid compounds can be produced, but flexible production of diverse collections with varying stereochemistry and functionality is insufficient
Solution Approach 1:
The patent develops universal synthetic pathways that can produce multiple classes of compounds (steroids, terpenoids, and their analogs) through common intermediate structures like the hydrindane core. This universality allows the same synthetic framework to generate diverse collections with varying stereochemistry, substitution patterns, and functionality by simply changing starting materials or reaction conditions.
Solution Approach 2:
The synthesis employs dynamic stereocontrol where the stereochemistry at quaternary centers can be adjusted by changing reaction conditions or catalysts at key steps. This dynamic approach enables flexible production of different stereoisomers and analogs from the same starting materials, greatly enhancing the versatility of the synthetic methodology.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods allow for the production of highly selective ERβ agonists that effectively inhibit the growth of glioma cells, providing a potential therapeutic avenue for treating brain tumors with improved selectivity and efficacy compared to existing treatments.
Implementation Method 1
intramolecular Friedel-Crafts alkylation
Implementation Method 2
Heck reactions
Implementation Method 3
oxidative dearomatization
Data Source
AI summary
The present disclosure relates to stereodefined polycyclic (e.g., tetracyclic) compounds that contain quaternary centers at one or multiple ring fusions, synthetic methods for preparing such compounds, and methods of using such compounds to treat a disease, such as a brain tumor and, particularly, a glioma.